Amaç: Perioküler bölgeye botulinum nörotoksin-A (BoNT-A) uygulamasının oküler yüzey konforu ve fonksiyonel kuru göz test sonuçları üzerine etkisini araştırmak. Gereç ve Yöntemler: Çalışmaya Ağustos 2023- Ocak 2024 tarihleri arasında göz hastalıkları kliniğimizde kozmetik amaçlı BoNT-A enjeksiyonu yapılan 38 kuru göz hastasının 38 gözü ve kontrol grubu olarak kuru göz hastalığı olmayan 39 katılımcının 39 gözü dâhil edildi. Katılımcıların BoNT-A enjeksiyonu öncesi ve enjeksiyon sonrası birinci ayda Schirmer testi, gözyaşı kırılma zamanı (GKZ), Oküler Yüzey Hastalık İndeksi [Ocular Surface Disease Index (OSDI®)] skoru ve en iyi düzeltilmiş görme keskinliği değerleri kaydedilerek grupların kendi içerisinde karşılaştırıldı. Bulgular: Ortalama Schirmer testi sonucu enjeksiyon öncesi ve enjeksiyon sonrası birinci ayda kuru göz grubunda sırasıyla 6,89±1,66 mm ve 5,60±1,25 mm; kontrol grubunda ise sırasıyla 22,00±7,18 mm ve 20,77±6,15 mm olarak ölçüldü. Schirmer değerinin iki grupta da enjeksiyon sonrasında anlamlı düzeyde azaldığı saptandı (sırasıyla p<0,001, p=0,003). Ortalama GKZ değeri enjeksiyon öncesi ve enjeksiyon sonrasında kuru göz grubunda sırasıyla 8,46±2,51 sn ve 7,35±1,83 sn, kontrol grubunda ise sırasıyla 14,55±3,57 sn ve 13,77±3,69 sn olarak saptandı. GKZ iki grupta da enjeksiyon öncesine göre anlamlı düzeyde düşük saptandı (sırasıyla p=0,001, p=0,014). Kuru göz grubunda ortalama OSDI® skoru enjeksiyon sonrasında anlamlı düzeyde artarken kontrol grubunda anlamlı farklılık saptanmadı (sırasıyla p=0,006 p=0,701). Sonuç: Perioküler bölgeye yapılan BoNT-A enjeksiyonu özellikle kuru göz hastalarında oküler yüzey ile ilgili yakınmalarda artışa ve fonksiyonel kuru göz testlerinde kötüleşmeye neden olmaktadır. Kuru göz hastaları BoNT-A enjeksiyonu öncesi bu konuda bilgilendirilmeli ve gerekli durumlarda kuru göz hastalığı tedavi planı gözden geçirilmelidir.
Anahtar Kelimeler: Botulinum toksinler, A tipi; kozmetikler; kuru göz sendromları; görme keskinliği
Objective: To investigate the effect of botulinum neurotoxinA (BoNT-A) application to the periocular region on ocular surface discomfort and functional dry eye test results. Material and Methods: The study included 38 eyes of 38 dry eye patients who received BoNT-A injection for cosmetic purposes in our ophthalmology clinic between August 2023 and January 2024, and 39 eyes of 39 participants without dry eye disease as a control group. Schirmer test, tear breakup time (TBUT), Ocular Surface Disease Index (OSDI®) score and best corrected visual acuity values of participants before BoNT-A injection and in first month after the injection were recorded and compared within groups. Results: The mean result of the Schirmer test was 6.89±1.66 mm in dry eye group before injection and 5.60±1.25 mm in first month after injection. In control group it was 22.00±7.18 mm and 20.77±6.15 mm respectively. It was found that Schirmer value decreased significantly in both groups after injection (p<0.001, p=0.003 respectively). Mean TBUT before and after injection was 8.46±2.51 seconds and 7.35±1.83 seconds in dry eye group and 14.55±3.57 seconds and 13.77±3.69 seconds in control group respectively. It was found that TBUT was significantly lower in both groups than before injection (p=0.001, p=0.014 respectively). While mean OSDI® score increased significantly after injection in dry eye group, no significant difference was found in control group (p=0.006, p=0.701 respectively). Conclusion: Injection of BoNT-A into periocular area leads to an increase in ocular surface discomfort and worsening of dry eye functional tests, especially in patients with dry eye. Patients with dry eye should be informed of this prior to BoNT-A injection and the treatment plan for dry eye disease should be reviewed as necessary.
Keywords: Botulinum toxins, type A; cosmetics; dry eye syndromes; visual acuity
- Craig JP, Nichols KK, Akpek EK, Caffery B, Dua HS, Joo CK, et al. TFOS DEWS II definition and classification report. Ocul Surf. 2017;15(3):276-83. [Crossref] [PubMed]
- Messmer EM. The pathophysiology, diagnosis, and treatment of dry eye disease. Dtsch Arztebl Int. 2015;112(5):71-81; quiz 82. [PubMed] [PMC]
- Clinch TE, Benedetto DA, Felberg NT, Laibson PR. Schirmer's test. A closer look. Arch Ophthalmol. 1983;101(9):1383-6. [Crossref] [PubMed]
- Paugh JR, Tse J, Nguyen T, Sasai A, Chen E, De Jesus MT, et al. Efficacy of the fluorescein tear breakup time test in dry eye. Cornea. 2020;39(1):92-8. [Crossref] [PubMed] [PMC]
- Schiffman RM, Christianson MD, Jacobsen G, Hirsch JD, Reis BL. Reliability and validity of the Ocular Surface Disease Index. Arch Ophthalmol. 2000;118(5):615-21. [Crossref] [PubMed]
- Horwath-Winter J, Bergloeff J, Floegel I, Haller-Schober EM, Schmut O. Botulinum toxin A treatment in patients suffering from blepharospasm and dry eye. Br J Ophthalmol. 2003;87(1):54-6. [Crossref] [PubMed] [PMC]
- Clark RP, Berris CE. Botulinum toxin: a treatment for facial asymmetry caused by facial nerve paralysis. Plast Reconstr Surg. 1989;84(2):353-5. [Crossref] [PubMed]
- Carruthers A, Carruthers J. History of the cosmetic use of Botulinum A exotoxin. Dermatol Surg. 1998;24(11):1168-70. [Crossref] [PubMed]
- Scott AB. Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. Ophthalmology. 1980;87(10):1044-9. [Crossref] [PubMed]
- Kaltreider SA, Kennedy RH, Woog JJ, Bradley EA, Custer PL, Meyer DR; American Academy of Ophthalmology; Ophthalmic Technology Assessment Committee Oculoplastics Panel. Cosmetic oculofacial applications of botulinum toxin: a report by the American Academy of Ophthalmology. Ophthalmology. 2005;112(6):1159-67. [Crossref] [PubMed]
- Kaynak-Hekimhan P. Noncosmetic periocular therapeutic applications of botulinum toxin. Middle East Afr J Ophthalmol. 2010;17(2):113-20. [Crossref] [PubMed] [PMC]
- Stapleton F, Alves M, Bunya VY, Jalbert I, Lekhanont K, Malet F, et al. TFOS DEWS II epidemiology report. Ocul Surf. 2017;15(3):334-65. [Crossref] [PubMed]
- American Society of Plastic Surgeons. American society of plastic surgeons 2016 National Clearinghouse of plastic Surgery statistics. [Cited: April 02,2024]. Available from: [Link]
- Wolffsohn JS, Arita R, Chalmers R, Djalilian A, Dogru M, Dumbleton K, et al. TFOS DEWS II Diagnostic Methodology report. Ocul Surf. 2017;15(3):539-74. [Crossref] [PubMed]
- Schirra F, Ruprecht KW. Das trockene Auge. Ein Update über Epidemiologie, Diagnose, Therapie und neue Konzepte [Dry eye. An update on epidemiology, diagnosis, therapy and new concepts]. Ophthalmologe. 2004;101(1):10-8. German. [Crossref] [PubMed]
- Rouen PA, White ML. Dry eye disease: prevalence, assessment, and management. Home Healthc Now. 2018;36(2):74-83. [Crossref] [PubMed]
- Dorizas A, Krueger N, Sadick NS. Aesthetic uses of the botulinum toxin. Dermatol Clin. 2014;32(1):23-36. [Crossref] [PubMed]
- Aoki KR, Ranoux D, Wissel J. Using translational medicine to understand clinical differences between botulinum toxin formulations. Eur J Neurol. 2006;13 Suppl 4:10-9. [Crossref] [PubMed]
- Lowe PL, Patnaik R, Lowe NJ. A comparison of two botulinum type a toxin preparations for the treatment of glabellar lines: double-blind, randomized, pilot study. Dermatol Surg. 2005;31(12):1651-4. [Crossref] [PubMed]
- The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf. 2007;5(2):75-92. [Crossref] [PubMed]
- Arat YO, Yen MT. Effect of botulinum toxin type a on tear production after treatment of lateral canthal rhytids. Ophthalmic Plast Reconstr Surg. 2007;23(1):22-4. [Crossref] [PubMed]
- Dutton JJ, Fowler AM. Botulinum toxin in ophthalmology. Surv Ophthalmol. 2007;52(1):13-31. [Crossref] [PubMed]
- Ozgur OK, Murariu D, Parsa AA, Parsa FD. Dry eye syndrome due to botulinum toxin type-A injection: guideline for prevention. Hawaii J Med Public Health. 2012;71(5):120-3. [PubMed] [PMC]
- Sahlin S, Chen E, Kaugesaar T, Almqvist H, Kjellberg K, Lennerstrand G. Effect of eyelid botulinum toxin injection on lacrimal drainage. Am J Ophthalmol. 2000;129(4):481-6. [Crossref] [PubMed]
- Choi MG, Yeo JH, Kang JW, Chun YS, Lee JK, Kim JC. Effects of botulinum toxin type A on the treatment of dry eye disease and tear cytokines. Graefes Arch Clin Exp Ophthalmol. 2019;257(2):331-8. [Crossref] [PubMed]
- Stevens S. Schirmer's test. Community Eye Health. 2011;24(76):45. [PubMed] [PMC]
- Koh S, Tung CI, Inoue Y, Jhanji V. Effects of tear film dynamics on quality of vision. Br J Ophthalmol. 2018;102(12):1615-20. [Crossref] [PubMed]
- Tong L, Chaurasia SS, Mehta JS, Beuerman RW. Screening for meibomian gland disease: its relation to dry eye subtypes and symptoms in a tertiary referral clinic in singapore. Invest Ophthalmol Vis Sci. 2010;51(7):3449-54. [Crossref] [PubMed]
.: Process List